REGN
Regeneron Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -28.6% ·
share flow -30.0% ·
net new positions -20.0%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 5 | -2 | 489.34K | $362.44M | n/a | −2 |
| Q2 2026 | 169 | -1 | 76.12M | $47.53B | +5 | −5 |
| Q1 2026 | 172 | -4 | 77.87M | $60.04B | +2 | −7 |
| Q4 2025 | 175 | 0 | 81.03M | $62.54B | +1 | n/a |
| Q3 2025 | 27 | -1 | 48.96M | $27.52B | n/a | −2 |
| Q2 2025 | 26 | +2 | 40.24M | $21.12B | +3 | −1 |
| Q1 2025 | 21 | +1 | 16.62M | $10.53B | +1 | n/a |
| Q4 2024 | 20 | -1 | 17.24M | $12.28B | n/a | −1 |
| Q3 2024 | 20 | +1 | 13.10M | $13.76B | +2 | −1 |
| Q2 2024 | 19 | n/a | 13.77M | $14.47B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Robeco Institutional Asset… | 402.96K | -12.5% | $305.55M | 0.4% | ▼ Trim | 4 | SEC ↗ |
| 2 | Assenagon Asset Management S.A. | 36.88K | -92.5% | $27.97M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 3 | Wealth Enhancement Advisory… | 37.20K | +9.8% | $19.59M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Assetmark, Inc | 12.28K | -2.5% | $9.31M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | TD Waterhouse Canada Inc. | 25 | +31.6% | $18,359 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Parnassus Investments, Llc | $59.47M | was 0.2% |
| Ninety One UK Ltd | $166,486 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,385 holders, 83.52M shares, $61.43B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 50 sh · $39,074
Officer · 127 sh · $97,701
Officer · 12 sh · $9,242
Officer · 283 sh · $218,351
Officer · 211 sh · $163,010
Officer · 224 sh · $173,242
Officer · 121 sh · $93,712
Officer · 376 sh · $291,573
Officer · 66 sh · $51,236
Officer · 38 sh · $29,555
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology